Among patients with AD, GLP-1 RAs reduced the risk for various MACE outcomes, including heart failure, cerebrovascular disease, and more.

The incidence of CRC was 0.130% and 0.176% among GLP-1 RA and aspirin users, respectively, yielding an adjusted risk ratio of 0.0455% and number needed to treat of 2198. HealthDay News — Glucagon-like ...

For adults with type 2 diabetes, discontinuation of GLP-1 RAs is associated with an increased risk for major adverse cardiovascular events.

Glucagon-like peptide-1 receptor agonist use is associated with delayed wound healing in patients undergoing abdominal panniculectomy.

In a review of adults treated with both a GLP-1 receptor agonist (RA) and a dermatologic biologic, most remained on combined therapy for a mean of 19 months, with relatively few discontinuations due ...

An observational study showed lower risks for lupus nephritis and systemic lupus erythematosus flare among patients with concomitant type 2 diabetes taking GLP-1 RA. Glucagon-like peptide-1 receptor ...

People with type 1 diabetes who took GLP-1 receptor agonist (GLP-1-RA) drugs for weight loss or better blood-sugar control had significantly reduced risks of major cardiovascular events and end-stage ...

Odds of vertebral compression fractures or surgical intervention were significantly lower among GLP-1 RA users. (HealthDay News) — Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) may protect ...

Findings seen among patients with chronic rhinosinusitis with nasal polyps and obesity. HealthDay News — Use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with reduced ...